Skip to main content

Table 2 Monthly transition probabilities of health states for patients on RRMM treatment [5, 30]

From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

DEX transition probabilities

Transition from

Transition to

0 < t \(\le\) 6

6 < t \(\le\) 26

 

26 < t \(\le\) infinity

Pre-prog

Prog

Dead

Pre-prog

Prog

Dead

Pre-prog

Progr

Dead

Pre-prog

0.80

0.19

0.02

0.86

0.14

0.00

0.92

0.08

0.00

Prog

0.00

0.88

0.12

0.00

0.95

0.05

0.00

0.94

0.06

Dead

0.00

0.00

1.00

0.00

0.00

1.00

0.00

0.00

1.00

BORT transition probabilities

Transition from

Transition to

0 < t \(\le\) 6

6 < t \(\le\) 26

26 < t \(\le\) infinity

Pre-prog

Prog

Dead

Pre-prog

Prog

Dead

Pre-prog

Progr

Dead

Pre-prog

0.88

0.10

0.01

0.92

0.08

0.00

0.96

0.04

0.00

Prog

0.00

0.90

0.10

0.00

0.96

0.04

0.00

0.95

0.05

Dead

0.00

0.00

1.00

0.00

0.00

1.00

0.00

0.00

1.00

LEN/DEX transition probabilities

Transition from

Transition to

0 < t \(\le\) 6

6 < t \(\le\) 26

26 < t \(\le\) infinity

Pre-prog

Prog

Dead

Pre-prog

Prog

Dead

Pre-prog

Progr

Dead

Pre-prog

0.92

0.07

0.01

0.95

0.05

0.00

0.97

0.03

0.00

Prog

0.00

0.92

0.09

0.00

0.97

0.03

0.00

0.96

0.04

Dead

0.00

0.00

1.00

0.00

0.00

1.00

0.00

0.00

1.00

  1. Pre-prog pre-progression, Prog progression, t time period in months